CorMedix Earnings Call Transcripts
Fiscal Year 2026
-
The company is expanding its institutional pharmaceutical portfolio following the Melinta acquisition, with REZZAYO's phase III prophylaxis data expected soon and DefenCath navigating a temporary reimbursement dip before a 2027 rebound. Pipeline growth includes a TPN indication, and financials remain strong with a $75M buyback program.
-
REZZAYO's phase III prophylaxis data is expected later in Q2, targeting a $2B+ TAM in transplant patients. DefenCath's launch is strong, with Medicare Advantage seen as a major growth driver, and the Melinta acquisition has stabilized revenue. Operational scaling will follow key clinical milestones.
-
The company has evolved into a diversified specialty pharma, expanding its institutional care portfolio and advancing key assets like REZZAYO and DefenCath. Strong clinical results, strategic reimbursement efforts, and a robust financial position support growth, with multiple catalysts expected in the next 12–18 months.
-
The company has transformed into a diversified specialty pharma platform, achieving record sales and integrating Melinta to expand its anti-infective portfolio. Rezzayo and DefenCath are positioned for significant growth in high-risk patient populations, with strong clinical and payer support, and multiple late-stage trials underway to address large unmet needs.
-
Record 2025 revenue was driven by DefenCath and Melinta, with 2026 guidance reflecting a transitional reimbursement period. Growth is expected from Rezzayo’s phase 3 readout, DefenCath’s TPN expansion, and strategic business development, supported by strong cash and IP positions.
Fiscal Year 2025
-
2025 saw record revenue growth and the Melinta acquisition, with strong Q4 results and robust cash flow. 2026 guidance is affirmed, though price erosion is expected post-TDAPA, and new product catalysts are anticipated. Active share repurchases and a strong pipeline support long-term growth.
-
Record Q3 2025 results driven by DefenCath and Melinta acquisition, with net revenue of $104.3M and net income of $108.6M. Raised full-year guidance and expect strong cash generation, while advancing late-stage pipeline and integration synergies.
-
A major acquisition has transformed the business into a multi-product company, with strong commercial momentum for DefenCath and a robust pipeline led by Roseo. Key milestones include Roseo phase 3 data in 2025, TPN study completion in 2026, and ongoing synergy capture from Millenta.
-
A recent acquisition has transformed the business into a multi-product hospital acute care platform, adding stable revenue and significant growth potential, especially for REZZAYO and DefenCath. Raised revenue guidance and ongoing clinical studies signal confidence in future expansion.
-
DefenCath launched commercially in 2024, targeting major dialysis operators and hospitals, with strong early revenue and expanding use. A phase three trial for TPN is underway, and new studies in pediatrics and high-risk groups are planned. Cash flow is positive, with robust market potential.
-
DefenCath’s commercial launch is progressing well, with strong adoption among major dialysis operators and robust first-half 2025 sales guidance. Expansion into inpatient and TPN markets, ongoing real-world evidence studies, and a lean cost structure position the company for continued growth and potential label expansion.
-
DefenCath, launched in mid-2024, rapidly achieved profitability and strong adoption in outpatient hemodialysis, with expansion into inpatient and new indications underway. Reimbursement strategies are adapting to evolving Medicare dynamics, and ongoing studies aim to demonstrate economic value. Ongoing growth and reinvestment are strategic priorities.
-
Q1 2025 saw net sales of $39.1M and net income of $20.6M, with strong DefenCath adoption led by U.S. Renal Care and growing inpatient penetration. Guidance for H1 2025 revenue was raised to $70M, and clinical programs advanced, including a new phase 3 study and expanded access initiatives.
-
Strong Q1 sales and increased guidance reflect robust demand for a newly launched catheter lock solution, with expansion into new indications and customers underway. Strategic partnerships, a solid cash position, and a focus on operational execution support continued growth and pipeline development.
-
DefenCath, a novel catheter lock solution, has achieved rapid commercial traction and break-even status, with strong adoption in outpatient hemodialysis and expansion into new indications like TPN and pediatrics. Strategic contracts, robust IP, and real-world evidence studies support long-term growth and standard-of-care ambitions.
Fiscal Year 2024
-
Q4 2024 marked the first profitable commercial quarter, with strong DefenCath uptake driving net revenue to $31.2 million and full-year revenue to $43.5 million. Outpatient sales led growth, while inpatient and new clinical initiatives are set to expand future revenue.
-
Q3 2024 saw $11.5M in revenue and a reduced net loss, driven by strong DefenCath outpatient adoption and new agreements expanding access to 60% of U.S. dialysis clinics. EBITDA positivity is expected in Q4, with continued high gross margins and robust cash reserves.
-
DefenCath's launch is progressing, with major outpatient contracts secured and shipments to high-risk patients expected in Q4. Real world evidence studies and label expansion into TPN are underway, while financials remain stable and execution is a key focus.
-
DefenCath's commercial launch drove $5.2M in early sales, with strong outpatient uptake and high clinic pull-through. Operating expenses rose due to launch activities, but cash reserves and projected sales are expected to fund operations and clinical trials through 2025.